Cannasouth Enters into Supply Agreement with MediPharm Labs Australia

  • May 04, 2020 NZST
  • Team Kalkine
Cannasouth Enters into Supply Agreement with MediPharm Labs Australia

Cannasouth Limited (NZX:CBD) has entered into a supply agreement with MediPharm Labs Australia Pty Ltd for the supply of white label medicinal cannabis products into the New Zealand Market.

  • Under the agreement, MediPharm Labs Australia will supply a range of products that meet the required high-quality standards;
  • During the two-year term of the agreement with MediPharm, Cannasouth will have exclusive rights to the formulation and dosage forms set out in the agreement for the New Zealand market.

At NZST 01:44 PM, the stock was trading at $0.500 per share, up by 8.70% from its previous close.



The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK